Equity Overview
Price & Market Data
Price: $3.23
Daily Change: +$0.28 / 8.67%
Range: $3.05 - $3.44
Market Cap: $92,718,936
Volume: 114,716
Performance Metrics
1 Week: 18.37%
1 Month: 10.20%
3 Months: 66.67%
6 Months: 7.37%
1 Year: 34.00%
YTD: 40.76%
Company Details
Employees: 49
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
OncoCyte Corporation, a precision diagnostics company in the United States and internationally. It develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. The company is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. It also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.